{
    "id": 11667,
    "fullName": "MYCN over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MYCN over exp indicates an over expression of the Mycn protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4613,
        "geneSymbol": "MYCN",
        "terms": [
            "MYCN",
            "bHLHe37",
            "MODED",
            "N-myc",
            "NMYC",
            "ODED"
        ]
    },
    "variant": "over exp",
    "createDate": "09/10/2015",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2803,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PW12 inhibited tumor growth in allograft models of medulloblastoma with heterozygous inactivating mutations in PTCH1 and TP53 and over expression of MYCN (PMID: 26029667).",
            "molecularProfile": {
                "id": 11726,
                "profileName": "MYCN over exp PTCH1 inact mut TP53 inact mut"
            },
            "therapy": {
                "id": 2961,
                "therapyName": "PW12",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3486,
                    "pubMedId": 26029667,
                    "title": "Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26029667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3412,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Alisertib (MLN8237) resulted in complete response in 63% (5/8) of mouse models of MYCN-driven neuroblastoma (PMID: 23792191).",
            "molecularProfile": {
                "id": 13311,
                "profileName": "MYCN over exp"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3772,
                    "pubMedId": 23792191,
                    "title": "Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23792191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11850,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a neuroblastoma transgenic mouse model overexpressing MYCN demonstrated a decrease in tumor volume when treated with CCT244747 (PMID: 22929806).",
            "molecularProfile": {
                "id": 13311,
                "profileName": "MYCN over exp"
            },
            "therapy": {
                "id": 4672,
                "therapyName": "CCT244747",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6590,
                    "pubMedId": 22929806,
                    "title": "CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22929806"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8156,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a TH-MYCN neuroblastoma mouse model demonstrated greater sensitivity to the combination treatment of Eflornithine and SAM486 compared to SAM486 alone, which showed a longer delay in tumor development and greater percentage reduction of tumor penetrance (PMID: 27012811).",
            "molecularProfile": {
                "id": 13311,
                "profileName": "MYCN over exp"
            },
            "therapy": {
                "id": 4650,
                "therapyName": "Eflornithine + SAM486",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6562,
                    "pubMedId": 27012811,
                    "title": "Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27012811"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5611,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, THZ1 inhibited proliferation of MYCN-overexpressing neuroblastoma cell lines in culture (PMID: 25416950).",
            "molecularProfile": {
                "id": 13311,
                "profileName": "MYCN over exp"
            },
            "therapy": {
                "id": 3908,
                "therapyName": "THZ1",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5125,
                    "pubMedId": 25416950,
                    "title": "CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25416950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9551,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SRA737 (CCT245737) resulted in decreased tumor volume in a neuroblastoma transgenic mouse model over expressing MYCN (PMID: 27167172).",
            "molecularProfile": {
                "id": 13311,
                "profileName": "MYCN over exp"
            },
            "therapy": {
                "id": 5069,
                "therapyName": "SRA737",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7267,
                    "pubMedId": 27167172,
                    "title": "Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27167172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8155,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a TH-MYCN neuroblastoma mouse model demonstrated sensitivity to treatment with SAM486, which showed delayed tumor development (PMID: 27012811).",
            "molecularProfile": {
                "id": 13311,
                "profileName": "MYCN over exp"
            },
            "therapy": {
                "id": 4649,
                "therapyName": "SAM486",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6562,
                    "pubMedId": 27012811,
                    "title": "Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27012811"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5302,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line with loss of TP53, MYCN over expression, and harboring DDR2 L63V demonstrated greater inhibition of tumor growth in xenograft models when treated with the combination of Sprycel (dasatinib) and JQ1 compared to either therapy alone (PMID: 26206333).",
            "molecularProfile": {
                "id": 20483,
                "profileName": "DDR2 L63V MYCN over exp TP53 loss"
            },
            "therapy": {
                "id": 3824,
                "therapyName": "Dasatinib + JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5000,
                    "pubMedId": 26206333,
                    "title": "NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206333"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8116,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Odomzo (sonidegib) inhibited survival of tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing wild-type Mycn in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26155,
                "profileName": "MYCN over exp PTCH1 inact mut"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16062,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with metastatic small-cell neuroendocrine prostate cancer with Aurka and Mycn protein overexpression and focal deletions in CDKN2A, CDKN2B, RB1, and BRCA2 tumor suppressor genes, had complete response of metastatic lesions and a sustained 8.3 month partial response to Alisertib (MLN8237) therapy prior to disease recurrence in the brain (PMID: 30232224; NCT30232224).",
            "molecularProfile": {
                "id": 31394,
                "profileName": "AURKA over exp MYCN over exp"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 2992,
                "name": "prostate neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14171,
                    "pubMedId": 30232224,
                    "title": "A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30232224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16064,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with metastatic small-cell neuroendocrine prostate cancer with Aurka and Mycn protein overexpression, deletions of FBXW7, FANCA, and SMARCB1, and loss of PTEN and CDKN2A, responded to Alisertib (MLN8237) therapy with complete resolution of metastasis in 12 weeks and a 14-month complete radiological response prior to discontinuation of therapy due to illness (PMID: 30232224; NCT30232224).",
            "molecularProfile": {
                "id": 31395,
                "profileName": "AURKA over exp FBXW7 del MYCN over exp"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 2992,
                "name": "prostate neuroendocrine neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14171,
                    "pubMedId": 30232224,
                    "title": "A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30232224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11726,
            "profileName": "MYCN over exp PTCH1 inact mut TP53 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13311,
            "profileName": "MYCN over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 6973,
                    "name": "BET  Inhibitor (Pan)",
                    "profileName": "MYCN over exp"
                },
                {
                    "id": 6972,
                    "name": "Aurka Inhibitors",
                    "profileName": "MYCN over exp"
                },
                {
                    "id": 6971,
                    "name": "AURK Inhibitor (Pan)",
                    "profileName": "MYCN over exp"
                }
            ]
        },
        {
            "id": 20483,
            "profileName": "DDR2 L63V MYCN over exp TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26155,
            "profileName": "MYCN over exp PTCH1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31394,
            "profileName": "AURKA over exp MYCN over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31395,
            "profileName": "AURKA over exp FBXW7 del MYCN over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}